The Archive · 3 posts
Discover groundbreaking biotech innovations! 🔬 ValiRx PLC (VAL) is pioneering advanced cancer therapies on the LSE. Join our mission to revolutionise health! 🌟
ValiRx 2025 results show cost cuts and pipeline progress, but a going concern warning highlights funding risks investors can't ignore.
June 22, 2026
Showing 2 of 3 posts
ValiRx's strategic evaluation of an oral RNA helicase cancer drug with McGill secures data rights and a path to equity, with built-in downside protection.
JoshuaJanuary 9, 2026
ValiRx cuts losses & boosts cash but auditors issue sobering going concern warning over future funding reliance. Key RNS insights.
JoshuaJune 6, 2025